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Abstract
Background: Pelvic floor muscle training is effective and recommended as first-line therapy for female patients
with stress urinary incontinence. However, standard pelvic floor physiotherapy concentrates on voluntary
contractions even though the situations provoking stress urinary incontinence (for example, sneezing, coughing,
running) require involuntary fast reflexive pelvic floor muscle contractions. Training procedures for involuntary
reflexive muscle contractions are widely implemented in rehabilitation and sports but not yet in pelvic floor
rehabilitation. Therefore, the research group developed a training protocol including standard physiotherapy and in
addition focused on involuntary reflexive pelvic floor muscle contractions.
Methods/design: The aim of the planned study is to compare this newly developed physiotherapy program
(experimental group) and the standard physiotherapy program (control group) regarding their effect on stress
urinary incontinence. The working hypothesis is that the experimental group focusing on involuntary reflexive
muscle contractions will have a higher improvement of continence measured by the International Consultation on
Incontinence Modular Questionnaire Urinary Incontinence (short form), and — regarding secondary and tertiary
outcomes — higher pelvic floor muscle activity during stress urinary incontinence provoking activities, better pad-
test results, higher quality of life scores (International Consultation on Incontinence Modular Questionnaire) and
higher intravaginal muscle strength (digitally tested) from before to after the intervention phase. This study is
designed as a prospective, triple-blinded (participant, investigator, outcome assessor), randomized controlled trial
with two physiotherapy intervention groups with a 6-month follow-up including 48 stress urinary incontinent
women per group. For both groups the intervention will last 16 weeks and will include 9 personal physiotherapy
consultations and 78 short home training sessions (weeks 1–5 3x/week, 3x/day; weeks 6–16 3x/week, 1x/day).
Thereafter both groups will continue with home training sessions (3x/week, 1x/day) until the 6-month follow-up.
To compare the primary outcome, International Consultation on Incontinence Modular Questionnaire (short form)
between and within the two groups at ten time points (before intervention, physiotherapy sessions 2–9, after
intervention) ANOVA models for longitudinal data will be applied.
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Discussion: This study closes a gap, as involuntary reflexive pelvic floor muscle training has not yet been included
in stress urinary incontinence physiotherapy, and if shown successful could be implemented in clinical practice
immediately.
Trial registration: NCT02318251; 4 December 2014
First patient randomized: 11 March 2015
Keywords: Electromyography, Exercise, Muscle contraction, Pelvic floor, Reflex
Background
Stress urinary incontinence (SUI), the most common urin-
ary incontinence subtype in women with a prevalence of
24.8 % [1], is defined as involuntary loss of urine during
effort or physical exertion (for example, during sporting
activities) or upon sneezing or coughing [2]. Activities typ-
ically provoking SUI raise the intra-abdominal pressure
and impact loading on the pelvic floor muscles (PFM) and
require strong, rapid, and reflexive PFM contractions to
maintain continence [3–6]. Fast and strong PFM contrac-
tions result in the generation of an adequate squeeze pres-
sure in the proximal urethra, which maintains a pressure
higher than that in the bladder, thus preventing leakage
[7]. PFM function regarding power (rate of force develop-
ment) is impaired in incontinent women compared to
continent women [4, 6].
PFM training — defined as a program of repeated vol-
untary PFM contractions taught and supervised by a
health care professional — is the most commonly used
physiotherapy treatment for women with SUI, is effect-
ive with all types of female incontinence, and, therefore,
is recommended as a first-line therapy [8, 9]. As en-
dorsed by the International Consultation on Incontin-
ence, PFM training should generally be the first step of
treatment before surgery [10]. However, standard SUI
physiotherapy concentrates on voluntary contractions
even though the situations provoking SUI such as sneez-
ing, coughing, jumping, and running [2] require involun-
tary fast reflexive PFM contractions [4]. Although
training procedures following the concepts of training
science and sports medicine are generally well known
and widely implemented in rehabilitation and sports
[11, 12], an optimal and well-standardized training
protocol for involuntary, fast, and reflexive PFM con-
tractions still remains unknown.
Consequently, the research group of the present study
developed a standardized therapy program, which in-
cludes the standard physiotherapy and additionally fo-
cuses on involuntary fast reflexive PFM contractions.
The additional exercises are well known and applied in
physiotherapy, however not yet regarding SUI.
Therefore, the aim of the present study is to compare
two different physiotherapy programs: standard training
plus involuntary reflexive PFM training versus standard
training alone, regarding their effect on SUI and the im-
pact of incontinence symptoms on quality of life. Both
programs include standard physiotherapy. Both follow
the concepts of training science, that is, periodization/
exercise sequence and training of specific muscle
strength components [11, 12]. One program focuses on
voluntary fast contractions (standard physiotherapy; con-
trol group); the other one additionally focuses on invol-
untary fast reflexive PFM contractions (experimental
group). The secondary objective, based on secondary
and tertiary outcomes, is a deeper insight into the func-
tioning of the PFM (PFM activity characteristics and
muscle action forms) by evaluating their activity mea-
sured by electromyography (EMG) in the quality of life
of patients with SUI and in patients’ therapy adherence.
Methods/design
Study design
The present study is a single-centered, prospective, triple-
blinded (participant, investigator, outcome assessor), par-
allel group, non-inferiority randomized controlled trial
with two physiotherapy intervention groups with a 6-
month follow-up.
Blinding
Participants will be blinded against the type of received
physiotherapy (control group, experimental group). The
participant information document will not provide any
information regarding the differences in the experimen-
tal and control therapy protocols in a way that women
could find out about their group allocation. All investi-
gators involved in data acquisition, data reduction, data
analyses, and statistics will also be blinded against group
allocation. The physiotherapists in charge of the therapy
cannot be blinded against group allocation and therefore
will not be involved in data acquisition, data reduction,
data analyses, or statistics.
Participants
With ethics committee approval (Ethics Committee of
the Canton of Bern reference number 249/14 on 12 No-
vember 2014; Chairperson Prof. Dr. Ch. Seiler), which is
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in accordance with the Declaration of Helsinki and the
Swiss Human Research Act, and written informed con-
sent, patients will be included on the condition that they
are female adults aged 18–70 years, suffer from SUI
(based on the patient’s history) or mixed urinary incon-
tinence (with dominant SUI), are one year post-partal,
parous, nulliparous, pre- or post-menopausal, have a
BMI of 18–30 kg/m2, are medically and physically fit for
the measurement and therapeutic exercises (running,
jumps), and, in case of systemic or local estrogen treat-
ment, stable for the past 3 months prior to inclusion.
Exclusion criteria are: urge incontinence or predomin-
ant urgency in incontinence; prolapse > grade 1 POP-Q
[13] (uterus, cystocele, rectocele during Valsalva maneu-
ver); pregnancy (urine test to accomplish); current urinary
tract or vaginal infection, menstruation on the day of
examination; lactation period not yet finished; contraindi-
cations for measurements or interventions, for example,
acute inflammatory or infectious disease, tumor, fracture;
de novo systemic or local estrogen treatment (<3 months);
de novo drug treatment with anticholinergics or other
bladder active substances (tricyclic antidepressants, select-
ive serotonin reuptake inhibitors). Interventions and mea-
surements would be individually modified in case of
temporary loss of physical fitness for certain exercises.
Outcomes
Primary outcome measure
The primary outcome measure will be the International
Consultation on Incontinence Modular Questionnaire
Urinary Incontinence short form (ICIQ-UIsf), which pro-
vides a brief and robust assessment of the impact of symp-
toms of urinary incontinence on quality of life and
outcome of treatment and is scored on a scale from 0
(not) – 21 (severely affected). Previous research has exam-
ined the ICIQ-UIsf questionnaire and found it to have
good reliability and constructive validity [14] and to cor-
relate well with urodynamic findings [15]. This question-
naire is validated in the German language [16]. For
measurement time points see Table 1.
Secondary and tertiary outcome measures
The secondary outcome measure will be the EMG activ-
ity of the PFM during rest, maximal voluntary contrac-
tions (MVCs), voluntary fast contractions (VFCs), and
during involuntary contractions during squat jumps
(SJs), counter movement jumps (CMJs), drop jumps
(DJs), and treadmill running at 7, 9, and 11 km/h [17].
As there is a relation between high impact activities and
SUI prevalence [18], those different and comprehensive
test exercises will be chosen to represent typical situa-
tions of involuntary urine loss and different muscle ac-
tion forms (isometric-concentric voluntary muscle
actions: MVC, VFC; involuntary eccentric-concentric
muscle actions: SJ, CMJ, DJ, running).
Additionally, the 20-min pad test [19, 20] and the
International Consultation on Incontinence Modular
Questionnaire Urinary Incontinence Symptoms Quality
of Life (ICIQ-LUTSqol) [21] will be implemented as sec-
ondary outcomes. The pad test will provide information
Table 1 Outcome measures and personal physiotherapy consultation time points
Baseline before
intervention phase
16-week intervention phase (1) after randomization into
control group and experimental group
After intervention
phase
6-month
follow-up
Visits 1 2 3 4 5 6 7 8 9 10 11 12
Weeks −1 1 2 4 6 8 10 12 14 16 16 + 1 16 + 26
Personal Physiotherapy Consultation (PT) PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8 PT9
Primary outcome
ICIO-UIsf x x x x x x x x x x
Secondary outcomes
EMG (rest, MVC) x x x
EMG (VFC, SJ, CMJ, DJ) x x x
EMG (running 7, 9, 11 km/h) x x x
ICIQ-UIsf x
ICIQ-LUTSqol x x x
20-min pad test x x x
Tertiary outcomes
Manual muscle testing x x x
Therapy adherence x x x x x x x x x x
ICIQ-UIsf International Consultation on Incontinence Modular Questionnaire Urinary Incontinence (short form), EMG electromyography, MVC maximal voluntary
contraction, VFC voluntary fast contraction, SJ squat jump, CMJ counter movement jump, DJ drop jump, ICIQ-LUTSqol International Consultation on Incontinence
Modular Questionnaire Urinary Incontinence Symptoms Quality of Life
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regarding the efficacy of the therapy protocols to the UI
symptoms (such as changes in the leakage volume)
and the ICIQ-LUTSqol evaluates the impact on the
participant’s quality of life with reference to social ef-
fects. It consists of 20 questions, which lead to a
summary score between 19 and 76 points (greater
values indicate higher impact on quality of life) and is
available in German [22].
As tertiary outcomes PFM strength will be digitally
assessed according to the Oxford Grading Scale [23],
and adherence to the home exercise program will be
assessed, that is, how many of the total therapy sessions
will be completed individually. The home exercise ad-
herence data will be collected with a simple training
diary questionnaire.
For measurement time points, see Table 1.
EMG procedure, instrumentation, and data reduction
Instrumentation
A vaginal surface EMG probe (3-pol-STIMPON® elec-
trode (Innocept Biobedded Medizintechnik GmbH,
Gladbeck, Germany) in a differential configuration will
be used to measure PFM activity. The STIMPON elec-
trode is a certified device (patent number EP 0 963 217
B1, CE 0482) which is widely applied in pelvic floor re-
habilitation. The probe is made of polypropylene and
with this soft surface therefore optimally designed to
adapt its form to individual vaginal cavities and not to
slip out of position during impact loads. The single ref-
erence adhesive surface electrode (Ambu Blue Sensor N,
Ballerup, Denmark) will be fixed on the right iliac crest.
Running will be conducted on a Kettler Marathon
TX1 treadmill device (Ense-Parsit, Germany) at speeds
of 7, 9, and 11 km/h and 1° inclination. For the DJ a 20-
cm step will be used.
To detect events necessary for the parameterization of
the time-dependent signals such as heel strike (= initial
contact = time point zero (T0)) during running, two load
cells (Type KMB52 K 10KN, Megatron, Putzbrunn,
Germany) are attached under the treadmill. T0 of SJ,
CMJ, and DJ will be identified by using a force plate
(Type 9286BA, Kistler Winterthur, Switzerland). Elec-
trodes will be connected to the transmitter by short wire
and the signals will be sent wirelessly to the receiver
(TeleMyo 2400 G2, Noraxon European Service Center,
Cologne, Germany).
EMG measurement procedures
The subjects will be instructed in the vaginal insertion
of the surface EMG probe using ultrasound lubrication
and will perform the insertion themselves after emptying
their bladder. They will wear a loose running suit and
running shoes of the same type but individual size. PFM
EMG will be measured for 30 seconds (s) without any
voluntary contraction and twice for 5 s during MVC
(contraction maximal as possible), which will be
instructed and controlled by intravaginal manual muscle
testing before the EMG measurements, and ten times
for VFC in a standing position, with a 15-s break be-
tween the single measurements. After that they will per-
form five SJs, five CMJs, and five DJs, again with 15 s
between the single measurements, each jump being
demonstrated and practiced before EMG recordings.
Thereafter, the subjects will perform a warm-up of
treadmill walking (5 km/h) for 30 s, then running at 7, 9,
and 11 km/h consecutively until they reach a steady
state. As soon as they reach the steady state at the re-
spective speed, the data acquisition will be started: all
data will be measured continuously for 10 s and the first
ten step cycles of the right leg will be analyzed. Between
the measurements of the different speeds the treadmill
will be stopped, followed by a 1-minute break until the
same procedure is restarted with the next speed [17].
Data reduction
All signals will be sampled at a rate of 3 kHz (sampling
interval (dt) equals 0.333 ms) using a measurement
amplifier and 1-bit analog-to-digital converter (ME-
2600i, SisNova Engineering, Zug, Switzerland) and the
software package “Analoge und digitale Signalverarbei-
tung” (ADS) version 1.12 (uk-labs, Kempen, Germany).
The EMG signals will firstly be first order high-pass
filtered with a cut-off frequency of 10 Hz by EMG pre-
amplifier leads to reject or eliminate artifacts and later
digitally low-pass filtered by Noraxon Receiver Hardware
with a cut-off frequency of 500 Hz. Secondly, to identify
amplitude peaks during MVC, EMG will be calculated
as RMS (200 ms moving window). 100 % of EMG equals
the average of the two peak amplitude values during the
two 5-s sessions of MVC. Thirdly, EMG variables of pre-
activity and reflexivity will be calculated as RMS values
within 30-ms intervals [24–26], averaged over 10 steps,
and normalized to peak MVC (% EMG). The variables
of pre-activity and reflexivity (30-ms intervals) will fol-
low former study protocol intervals [17, 24, 25]. All vari-
ables will be analyzed using the software package
MATLAB (MathWorks, Natick, MA, USA). Outcomes
will be averaged over the repetitions of each exercise.
Statistical methods
Hypothesis
Alternative hypothesis for primary outcome: It is
hypothezised that the experimental group focusing on
involuntary pelvic floor muscle contractions will have a
statistically higher improvement of continence measured
by ICIQ-UIsf questionnaire from before to after the
intervention phase.
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Sample size calculation
Sample size calculation was performed with G*Power soft-
ware [27], using the statistical model of an ANOVA ap-
proach (repeated measures, within-between interactions).
To this day there is no comparable training study (RCT)
to estimate sample size based on available data from
ICIQ-UIsf. Consequently, sample size was estimated the-
oretically and an effect size of = 0.1, indicating a small ef-
fect [28] will be accepted. The sample size was calculated
for the primary outcome ICIQ-UIsf with the following as-
sumptions: α = 0.05, power (1–β error probability) = 0.8,
number of groups = 2, number of measurements = 10;
correlations among repeated measures were estimated
conservatively low with 0.5. Based on these assumptions, a
total sample size of N = 80 was estimated. In anticipation
of dropouts (10 %: n = 8) or a violation of normality
assumption (+10 %: +n = 8), a final sample size of N = 96
(48 participants per group) results.
Statistical analyses
Analysis of the patients will follow the CONSORT flow
diagram (see Fig. 1) through the phases of the study
(enrollment (assessed, excluded, randomized), allocation
(control group, experimental group with received inter-
vention or not received intervention), follow-up (lost to
follow-up, discontinued intervention), and analysis (ex-
cluded, included)) [29].
The outcomes of the control and experimental group
will be analyzed by the repeated measures within-between
interactions ANOVA approach and an intention-to-treat
analysis (last observation carried forward method). No
subgroup analyses are planned.
Primary analysis: For the descriptive analyses means,
standard deviations, 95 % confidence intervals, and me-
dian, quartiles, minima, maxima will be used.
To compare the primary outcome ICIQ-UIsf between
and within the two groups (control group, experimental
group) at ten time points (before intervention, physio-
therapy sessions 2–9, after intervention), ANOVA
models for longitudinal data according to Brunner et al.
[30] will be used. All statistical analyses will be realized
after the final measurement of the last patient at the
time point after intervention. The statistics will be calcu-
lated by SPSS and R software packages in the current
Fig. 1 CONSORT study flow diagram
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versions. The repeated measure design with ten time
points allows us to monitor how patients change over
time, in both short-term (before/during intervention)
and long-term situations (before/after intervention).
Secondary and tertiary analyses: All secondary and ter-
tiary outcomes will be analyzed following the same ap-
proach and with the same statistical procedures as for
primary outcomes. Generally, rational data will be
checked for normality using Q-Q-plots. If the normality
assumption is not violated, parametric ANOVA models
for longitudinal data will be used [31]. As for intra-
session retest procedures (EMG amplitude and fre-
quency), data will also be described and checked for
their reliability (ICC, SEM, MD, ANOVA).
Detailed study plan
Patient recruitment/consent procedure
Patients will be recruited from the urogynecology con-
sultation of the Women’s Hospital, Bern University Hos-
pital and University of Bern, Switzerland. All
participants for the study will be provided a participant
information sheet and a consent form describing the
study and providing sufficient information for them to
make an informed decision about their participation in
the study.
Each participant will be specifically informed that the
participation in the study is voluntary and that she may
withdraw from the study at any time and that with-
drawal of consent will not affect her subsequent medical
assistance and treatment.
Allocation of patients
Patients with written informed consent are randomly al-
located to one of the two therapy groups (control group,
experimental group). The allocation sequence will be
generated by the independent urogynecology secretariat
using online randomization software (http://randomiza-
tion.com); allocation ratio = 1:1 (control group:experi-
mental group). The allocation will be concealed in
sealed, opaque, sequentially numbered envelopes, which
will be stored at the secretariat and can be opened one
at a time for each eligible patient. Physiotherapists treat-
ing patients will be informed about enrollment and
group allocation of their patient by the independent
secretariat.
Outcome measurements
Baseline (before intervention phase), after intervention
phase, and 6-month follow-up measurements (of pri-
mary, secondary, and tertiary outcomes) will take place
at the Bern University of Applied Sciences movement
laboratory by two experienced pelvic floor physical
therapists, who are blinded regarding group allocation
of participants. Measurements during the 16-week
intervention phase (ICIQ-UIsf; primary outcome) will
be taken by the treating physiotherapists. However, to
guarantee blinding of the outcome, the participant
will fill in the questionnaire in the absence of the
treating physiotherapist and seal it in an envelope,
which will be given to the outcome assessor.
Intervention
Both therapy programs (control group, experimental
group) are based on the latest position stand paper of
the American College of Sports Medicine [11, 32], PFM
motor learning concepts [33, 34], and strength training
concepts [11, 12, 32, 35, 36]. The planned progression of
training for strength, power, and hypertrophy [11, 32, 33,
35, 36] is shown in Table 2.
Training procedures for motor learning, strength,
hypertrophy, and power training phases follow the train-
ing principles of variation/periodization, muscle action
and velocity of muscle action, loading, volume, exercise
selection, rest period, and frequency [11, 12] for both
groups. The training program will last 16 weeks and will
contain 9 personal physiotherapy consultations and 78
home training sessions of approximately 15 minutes
(weeks 1–5 3x/week, 3x/day; weeks 6–16 3x/week, 1x/
day) (Tables 1 and 2). Motor learning and strength and
hypertrophy phases are comparable for both groups.
However, the main difference between the programs is
the applied type of muscle action (control group: isomet-
ric, concentric; experimental group: isometric, concen-
tric, eccentric und eccentric-concentric) and speed of
movement (control group: voluntary slow to moderate
(to explosive) [33, 35]; experimental group: explosive, re-
active, reflexive). After completion of the 16-week train-
ing program, the participants will participate in no
further personal physiotherapy consultations; however,
they will continue home training sessions 3x/week until
the 6-month follow-up. During the intervention period
participants may continue with their individual activities
of daily life.
The personal physiotherapy consultations will take
place in the physiotherapy center of the Women’s
Hospital, Bern University Hospital and University of
Bern, Switzerland. The treating physiotherapists are
all specialized and experienced in PFM rehabilitation.
An additional document file presents the intervention
(therapy plan of intervention group and control group)
in detail [see Additional file 1].
Adverse events
In the current study there are no anticipated risks or in-
conveniences, as the applied intervention and examina-
tions are well known and widely applied in pelvic floor
standard physiotherapy. The additional exercises of the
experimental group are also well known and applied in
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physiotherapy; however, they have not yet been used
with SUI patients.
All the women are asked during every personal physio-
therapy and measurement consultation whether they ex-
perience any adverse effects.
Ethical approval
The present randomized controlled trial has been ap-
proved by the ethics committee of the Canton of Bern
(reference number 249/14 on 12 November 2014). The
original title of the study approved by the ethics com-
mittee of the Canton of Bern, Switzerland and the Swiss
National Science Foundation was: “Stress urinary incon-
tinence physiotherapy: study protocol for a randomized
controlled trial with 6-month follow-up.”
A summary flow chart is provided in Fig. 1 (CON-
SORT study flow diagram).
Discussion
SUI is increasingly recognized as a health and economic
problem which not only troubles the affected women,
but also implies a substantial economic burden on
health and social services [37]. Physiotherapy, the first-
line basic SUI therapy [8, 9], represents only a mere 2 %
of total costs [38] and therefore seems to be good value
for the money. As activities or efforts typically provoking
SUI occur within milliseconds [39, 40], the focus of
physiotherapy PFM training protocols on fast and reflex-
ive contractions seems crucial for SUI patients. To the
best of the authors’ knowledge, the present study is the
first one investigating a PFM protocol focusing on PFM
reactivity, that is, investigating involuntary PFM contrac-
tions rather than concentrating exclusively on PFM vol-
untary contractions (standard physiotherapy). Should
this newly developed PFM therapy protocol be shown
successful, the clinical impact would be high and the
application in clinical practice and therefore the bene-
fit for SUI patients immediate. Additionally, the new
therapy protocol promises to gain high acceptance by
patients as it offers a higher suitability and practic-
ability for daily use, because it has more dynamic
whole body movement elements integrated than does
standard SUI physiotherapy.
Trial status
First patient randomized on 11 March 2015
Trial protocol and updates: see clinicaltrials.gov.
Additional file
Additional file 1: Stress Urinary Incontinence Physiotherapy -
Therapy Plan. (PDF 524 kb)
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